IPD Meta-analysis of De-escalation Treatment Strategy After PCI in ACS
Comparison of De-escalation Treatment Strategy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome
1 other identifier
observational
9,000
1 country
1
Brief Summary
We will perform a systemic review of previously published data and an updated patient-level meta-analysis of studies, including the most recent publications. PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes of Health registry of clinical trials, and relevant websites were searched for pertinent published studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2021
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedStudy Start
First participant enrolled
June 7, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJune 8, 2021
June 1, 2021
3 months
April 10, 2021
June 7, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Net adverse clinical and cerebral events (NACCE)
composite of all-cause death, myocardial infarction, coronary revascularization, stroke and major bleeding.
1 year after intervention
Secondary Outcomes (9)
Composite endpoint of Major adverse cardiovascular outcomes
1 year after intervention
Major Bleeding outcome defined by the Bleeding Academic Research Consortium (BARC) criteria
1 year after intervention
Individual components of the primary outcome
1 year after intervention
Individual components of the primary outcome
1 year after intervention
Individual components of the primary outcome
1 year after intervention
- +4 more secondary outcomes
Study Arms (2)
De-escalation treatment group
Patients diagnosed as acute coronary syndrome, and who receive de-escalation antiplatelet therapy after percutaneous coronary intervention
Conventional treatment group
Patients diagnosed as acute coronary syndrome, and who receive conventional (non-de-escalation) antiplatelet therapy after percutaneous coronary intervention
Interventions
Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
Eligibility Criteria
As above
You may qualify if:
- Subject must have clinical diagnosis of acute coronary syndrome
You may not qualify if:
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seoul National University Hospitallead
- St. Antonius Hospitalcollaborator
- Ludwig-Maximilians - University of Munichcollaborator
Study Sites (1)
Seoul National University Hospital
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kyung Woo Park, MD, PhD
Seoul National University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 10, 2021
First Posted
April 19, 2021
Study Start
June 7, 2021
Primary Completion
September 1, 2021
Study Completion
December 1, 2021
Last Updated
June 8, 2021
Record last verified: 2021-06